Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cutia TherapeuticsHKSE:02487 +6.10%40 Days Payable is 14.22 as of Dec. 2025, which is 68% below its 10-year median of 45.05. GuruFocus rates HKSE:02487 with a GF Score™ of 40/100 and a GF Value™ of HK$16.27 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Cutia Therapeutics ranks worse than 84.76% on this metric.
The historical rank and industry rank for Cutia Therapeutics's Days Payable or its related term are showing as below:
HKSE:02487'
s Days Payable Range Over the Past 10 Years
Min: 25.14 Med: 45.05 Max: 285.59
Current: 25.14
During the past 5 years, Cutia Therapeutics's highest Days Payable was 285.59. The lowest was 25.14. And the median was 45.05.
HKSE:02487's Days Payable is ranked worse than 84.76% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs HKSE:02487: 25.14
Cutia Therapeutics's Days Payable
declined
from Dec. 2024 (17.58) to Dec. 2025 (14.22).
It may suggest that Cutia Therapeuticsaccelerated paying its suppliers.
Cutia Therapeutics Days Payable Related Terms
Cutia Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02487 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Cutia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cutia Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) has a Days Payable of 14.22 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cutia Therapeutics and its competitors. This is 68% below median its historical median of 45.05. Over the past decade, Cutia Therapeutics' Days Payable has ranged from 25.14 to 285.59. According to the industry distribution chart, Cutia Therapeutics ranks #595 out of 702 companies in the Biotechnology industry, placing it in the top 84.8%.
Is Cutia Therapeutics' Days Payable too high?
Cutia Therapeutics' current Days Payable of 14.22 is 68% below median its 10-year median of 45.05. Over the past 10 years, this metric has ranged from a low of 25.14 to a high of 285.59. The Biotechnology industry median Days Payable is 113.10. Cutia Therapeutics' value of 14.22 is 87.4% below this industry median. Based on the distribution chart, Cutia Therapeutics ranks #595 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #595 out of 702 companies for Days Payable. This places Cutia Therapeutics in the lower half of its industry. The industry median Days Payable is 113.10. Cutia Therapeutics' value of 14.22 is 87.4% below this benchmark. Historically, Cutia Therapeutics' own Days Payable has ranged from 25.14 to 285.59 over the past decade. While the company's 10-year median is 45.05 vs. the industry median of 113.10, Cutia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cutia Therapeutics's current Days Payable of 14.22 is 87.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cutia Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current Days Payable is 14.22, which is 68% below median its own 10-year median of 45.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current Days Payable is 14.22, which is 68% below median its 10-year median of 45.05 and 87.4% below the Biotechnology industry median of 113.10. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Days Payable is 14.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
Days Payable: 14.22 (68% below median its 10-year median of 45.05)
GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
Industry Position: 87.4% below the Biotechnology median (#595 of 702)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score
Get the complete analysis for HKSE:02487
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
